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Abstract: Scopolamine hydrobromide (SH)-loaded microparticles were prepared from a 
  colloidal fluid containing ionotropic-gelated chitosan nanoparticles using a spray-drying method. 
The spray-dried microparticles were then formulated into orally disintegrating tablets (ODTs) 
using a wet granulation tablet formation process. A drug entrapment efficiency of about 90% 
(w/w) and loading capacity of 20% (w/w) were achieved for the microparticles, which ranged 
from 2 µm to 8 µm in diameter. Results of disintegration tests showed that the formulated ODTs 
could be completely dissolved within 45 seconds. Drug dissolution profiles suggested that SH 
is released more slowly from tablets made using the microencapsulation process compared with 
tablets containing SH that is free or in the form of nanoparticles. The time it took for 90% of the 
drug to be released increased significantly from 3 minutes for conventional ODTs to 90 minutes 
for ODTs with crosslinked microparticles. Compared with ODTs made with noncrosslinked 
microparticles, it was thus possible to achieve an even lower drug release rate using tablets with 
appropriate chitosan crosslinking. Results obtained indicate that the development of new ODTs 
designed with crosslinked microparticles might be a rational way to overcome the unwanted 
taste of conventional ODTs and the side effects related to SH’s intrinsic characteristics.
Keywords: scopolamine hydrobromide, chitosan, nanoparticles-in-microparticles system, 
spray-drying, orally disintegrating tablets
Introduction
Because of lifestyle changes, a demand has arisen for the development of pharmaceuti-
cal forms that can be readily handled and taken by many patients. Rapidly disintegrating 
or dissolving drug delivery systems, in which drugs are administrated orally for direct 
ingestion without water, are particularly useful for geriatric, pediatric, and traveling 
patients. These new forms of medicine are quite advantageous because they can be 
taken without any chewing or prior dispersion and/or dissolution processes.1–3 Some 
of them (sublingual or buccal tablets) display a spontaneous deaggregation and fast 
absorption in the mouth upon contact with saliva.4 Therefore, numerous studies on 
various compositions and manufacturing methods of orally disintegrating or dissolv-
ing tablets (ODTs) have been performed.5,6 Unfortunately, the quickly disintegrating 
dosage forms usually have an unpleasant taste, local stimulation, and other side effects 
caused by short, intense exposure to high concentrations of the active agent.
Microencapsulation is a new technique that could be used to control the drug release 
rate, protect it from premature destruction, and avoid the unpleasant taste by entrapping International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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the active drug into a microcarrier.7 Spherically shaped and 
  surface-distorted microparticles (embedded with the drug) could 
lessen the unwanted effects of ODTs by controlling the drug 
release rate. Recently, a novel nanoparticles-in-microparticles 
system (NiMS) has been developed using a double emulsion-
like technique and evaluated for drug and gene delivery in 
specific regions of the gastrointestinal tract.8,9 This NiMS might 
give valuable hints for the development of new drug-loaded 
ODTs. However, as far as we know, few reports have made 
mention of this new formulation design.
Chitosan (CS), a biocompatible and biodegradable poly-
saccharide, is widely used in the development of drug deliv-
ery systems.10 Our recent work has established a CS-based 
NiMS that displays high drug entrapment efficiency and 
controlled drug release.11,12 The obtained results are quite 
encouraging, in terms of the further application of NiMS 
for oral drug delivery.
Scopolamine, also known as levo-duboisine and hyo-
scine, is a tropane alkaloid drug that acts as a nonselec-
tive muscarinic antagonist and is used extensively in the 
clinic to treat motion sickness. It is obtained from plants 
of the Solanaceae (nightshades) family, such as henbane, 
weed, Angel’s Trumpets (Datura resp. Brugmansia spec.), 
and corkwood (Duboisia species).13 Scopolamine can be 
administered by transdermal, oral, subcutaneous, ophthal-
mic, and intravenous routes. The oral, ophthalmic, and 
intravenous forms of the drug are usually scopolamine 
hydrobromide (SH). The commonly observed side effects 
are related to anticholinergic effects on postsynaptic recep-
tors in the parasympathetic nervous system and include 
the following: dry mouth, throat, and nasal passages; in 
cases of overdose, impaired speech, thirst, blurred vision, 
and sensitivity to light; constipation; difficult urinating; 
and tachycardia. As for the fast disintegration behavior 
of conventional SH ODTs, the initial burst-released drug 
could be absorbed very quickly and result in high serum 
concentration. Then, an unpleasant taste and the aforemen-
tioned side effects of SH are inevitable. So it is desirable 
to design and develop a rational delivery system for SH 
using NiMS-based ODTs.
In the present study, to minimize the encountered side 
effects, a CS-based NiMS was prepared and used to encap-
sulate the model drug SH through an ionotropic gelation 
process followed by spray-drying. Orally disintegrating 
technology was then applied to construct orally disintegrating 
microparticle tablets (ODMTs) using a wet granule compres-
sion method. To compare these tablets with conventional 
ODTs, in vitro disintegration tests and drug release studies 
were also performed.
Materials and methods
Materials
CS that was over 95% deacetylated and had a molecular 
weight of 40–80 kDa was supplied by RuJi Biopharma-
ceutical Co. (Shanghai, People’s Republic of China). 
  Tripolyphosphate pentasodium (TPP) and polyvinylpyr-
rolidone K30 were obtained from the Chemical Agent 
Station, Medicine Group of China (Shanghai). SH was 
obtained from HuanYe Pharmaceutical Co. Ltd (Guangzhou, 
People’s Republic of China). Xylitol (Danisco Sweeteners 
Co. Ltd, Anyang, People’s Republic of China), microcrys-
talline cellulose (USP/JRS, Shanghai), carboxymethylstarch 
sodium (USP/YongRi, Taiwan, People’s Republic of China), 
  mannitol (LanJi Technological Co. Ltd, Shanghai), and gum 
arabic (USP/A250, Degussa, Germany) were also purchased 
for use as tablet adjuvants. All other chemicals were of 
reagent grade and used as provided by the manufacturer.
Preparation of sh-loaded  
cs nanoparticles
Ionotropic gelation for the formation of CS nanoparticles 
(CS-NPs) was performed as previously described.11,12,14 CS 
solution (0.5%, w/v) was obtained by dissolving CS in dilute 
acetic acid (0.3%, v/v) at room temperature overnight and 
passed through a 0.22 µm filter to remove insolubles. SH 
had been previously dissolved into this CS solution at the 
CS/SH ratio of 4:1 (w/w) to obtain a homogenous   mixture. 
Then, TPP was directly dissolved in distilled water at 
2 mg/mL (w/v). Thereafter, the ionic gelification of CS in 
the aqueous medium was achieved by the addition of TPP 
solution (3 mL/min) corresponding to the CS solution and 
magnetically stirred (900 rpm) at room temperature. The 
ratio of CS/TPP was kept at 6:1 (w/w) for the construction 
of CS-NPs in both formulations. Thereafter, the resulting 
colloidal CS-NPs were continuously stirred for 30 minutes, 
and the product was stored at room temperature until the next 
microencapsulation step.
Preparation of sh-loaded cs 
microparticles by spray-drying
The obtained aqueous mixture of CS-NP colloids (including 
the NPs, drug not entrapped, and free CS), without centrifuga-
tion, was spray-dried (Büchi® Mini Spray Dryer, Type 290, 
  Switzerland) at a feed rate of 6.0 mL/min. The   spray-drying International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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  conditions were inlet temperature 128–132°C, outlet   temperature 
68–71°C, aspirator 90%, pump feed 20%, and Q flow 45. 
Finally, the product was kept under vacuum for 48 hours and 
stored in a desiccator at room temperature until use.
For use as a control, noncrosslinked CS microparticles 
(made without the addition of the TPP crosslinking agent) 
were prepared by spray-drying the aqueous sample made by 
mixing the drug directly with the CS solution.
Drug encapsulation efficiency  
and loading capacity
For the nanosuspension sample, the amount of drug entrapped 
was calculated as the difference between the total amount 
used and the amount presented in the centrifuged aqueous 
supernatant phase.15 Then, the SH efficiency and load-
ing capacity was determined directly in the spray-dried 
  particles.16 After extraction by sonication for 30 minutes 
with 0.3% (v/v) acetic acid solution, the drug encapsulation 
efficiency and the loading capacity of the microparticles 
were determined by analysis of the samples in suspension 
after centrifugation at 20,000 × g and 12°C for 30 minutes. 
The extracted SH in the supernatant after ultracentrifugation 
of the microparticle suspension was determined using the 
high-performance liquid chromatography (HPLC) method 
described here. Each sample was assayed in triplicate.
The HPLC analyses were carried out using a   system 
(Shimadzu, LC-10A, Japan) that consisted of two LC-10AT 
pumps (Shimadzu), a Rheodyne 7125 manual injection 
valve with 20 µL sample loop, an SPD-10A UV detec-
tor (Shimadzu), and a C-18 reversed-phase column 
(4.6 mm × 200 mm, 5 µm, Hypersil ODS). The mobile phase 
was a mixture of methanol and 2 mmol/L ammonium acetate 
solution (40:60, v/v; pH 3.3). The flow rate was 1.0 mL/min 
at 25°C, and the wavelength was set at 210 nm.
The drug loading capacity (LC) of the microparticles 
and the encapsulation efficiency (EE) of the process were 
calculated according to the following equation:
LC = Ddetermined SH /Wmp × 100%; 
EE = Ddetermined SH /Wtotal SH × 100%
where Ddetermined SH is the determined amount of SH extracted 
from microparticles, Wtotal SH is the total amount of SH added, 
and Wmp is the weight of the microparticles.
scanning electron microscopy
The morphology and surface appearance of the spray-dried 
microparticles were studied by scanning electron microscopy 
(SEM, XL-30E, Philips, the Netherlands). The powdered 
sample was placed on double-sided tape that had previously 
been secured on aluminum stubs and then observed using 
SEM at an acceleration voltage of 15 kV after gold sputter-
ing and under argon.
Drug release from the microparticles  
in vitro
The in vitro drug release profiles of SH-loaded micropar-
ticles were carried out as described here. About 30 mg of 
microparticles was placed into a dialysis membrane bag that 
was impermeable to molecules weighing more than 8 kDa. 
Then, the bag containing the SH microparticles was tied 
and put into 100 mL of phosphate-buffered saline (PBS, 
pH 6.8). The entire system was incubated at 37°C ± 1°C 
with stirring at 50 rpm. At designated time intervals, 
0.5 mL of the release medium was removed and replaced 
with the same volume of fresh PBS. The amount of SH in 
the release medium was determined by HPLC under the 
described chromatographic conditions. All measurements 
were performed in triplicate.
Manufacture of sh-cs microparticle-
based ODMTs
A wet granulation compression method was used to prepare 
the ODTs. First, the powdered drug-loaded NiMS and the 
various quickly disintegrating tablet adjuvants (with appro-
priate amounts of diluent, disaggregating agent, and lubricant 
at the specified ratios listed in Table 1) were screened to 
produce a homogeneous mixture. The resulting mixtures 
were passed through a 30-mesh sieve with openings of less 
than 600 µm in diameter and then granulated in a mortar 
using 10% (w/v) polyvinylpyrrolidone K30 ethanol solution 
(95%, v/v) as an adhesive. The obtained granulates were 
dried in a 60°C oven for 1 hour. The final granules were then 
passed through a 14-mesh sieve and stored in a desiccator at 
room temperature until use.
The filtered dry granules were directly compressed using 
a single-punch tablet formation machine (Tianxiang Jiantai 
Machinery Drug Making Co., Shanghai) fitted with a 5 mm 
diameter normal biconcave punch and die set. Relatively 
constant tablet hardness was maintained at around 8 kg 
  (measured on a 78X-2 multifunctional determinator for tab-
lets, Huanghai, People’s Republic of China) for compression. 
All tablets generated using this method contained 0.2 mg of 
entrapped active drug. The complete compositions of these 
tablets are shown in Table 1.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Determination of disintegration time
The disaggregation tests for ODTs were performed at 37°C 
using a disintegration time determinator (LB-2D, Huanghai 
Drug Testing Instrument Co. Ltd, Shanghai) and purified 
water as a dispersion medium. The disintegration time is the 
time required to transform a tablet immersed in water into 
small fragments with vertical vibrations at a rate of 30 vibra-
tions per minute. The disintegration time of each formulation 
was recorded (n = 6).
Dissolution testing of the prepared tablets
The dissolution tests of the prepared tablets were performed 
at 37°C ± 1°C using a stir method (50 rpm) with 10 mL 
phosphate buffer (pH 6.8) as a dissolution medium. At pre-
determined time intervals, 0.5 mL of the release medium 
was sampled and filtered. The filtrates were analyzed by the 
HPLC method described previously. It is worth noting that 
none of the additives used in the formulations interfered 
with the assay. The results are expressed as the percentage 
of released drug as a function of time.
statistical analysis
Data were expressed as mean ± standard deviation. Results of 
the in vitro drug release studies were analyzed using F-test. 
Differences were considered to be significant at a level of 
P , 0.05.
Results and discussion
cs nanoparticles and the resulting 
microparticles constructed by direct 
spray-drying
TPP is a nontoxic and multivalent anion that can form cross-
linkages involving ionic interactions between the positively 
charged amino groups of CS and multivalent, negatively 
charged TPP molecules.17,18 With the dropwise addition of 
TPP, the nanoencapsulation was processed with the electro-
static attraction. Meanwhile, with the incorporation of ion 
TPP to CS solution, the opalescence indicated the formation 
process of nanoparticles with a size range of 200–500 nm, 
a mean diameter of approximately 350 nm, and positive 
charge of 17 mV , analyzed with a NicompTM 380 ZLS Coulter 
(Santa Barbara, CA). As observed from the transmission elec-
tron microscopic (H-600 Hitachi, Japan) image in Figure 1, 
the SH-loaded CS-NPs had a regular spherical shape with 
a relatively narrow size distribution. During the ionotropic 
gelation process, most of the available CS was formed into 
nanoparticles, and a particle containing more than 80% of 
the CS (as measured by a bicinchoninic acid protein assay) 
was generated. In this case, the TPP reacted with a large 
amount of the CS, resulting in the formation of gelated 
nanoparticles. TPP-crosslinked CS-NPs and their conver-
sion into spray-dried microparticles are expected to improve 
the particles’ stability and applicability for controlled drug 
delivery. Following the ionotropic gelation process using 
TPP as a crosslinking agent, the spray-drying method was 
performed to reinforce the formation of drug-loaded CS 
microbeads. The spray-dried NiMS powder might as well 
have some merits for tablet formulation and granulation. 
Meanwhile, the disintegrated microparticles might be capable 
Table 1 Percentage composition of the orally disintegrating tablet formulations investigated
Component Form of SH Microcrystalline 
cellulose (%)a
Carboxymethyl 
starch sodium (%)a
Mannitol  
(%)a
Xylitol  
(%)a
Lactose  
(%)a
Magnesium 
stearate (%)a
Function Active drug Deaggregant Deaggregant Sweetener Corrigent Diluent Lubricant
Formulation A Original sh 35 10 45 1 5 0.5
Formulation B sh-NiMs 35 10 45 1 5 0.5
Formulation c sh microparticles 35 10 45 1 5 0.5
Note: aThe percentage stands for weight ratio of one component to total (w/w).
Abbreviations: NiMs, nanoparticles-in-microparticles system; sh, scopolamine hydrobromide.
Figure  1  Transmission  electron  microscope  photograph  of  scopolamine 
hydrobromide-loaded  chitosan  nanoparticles  (×30,000)  prepared  by  ionotropic 
gelation process.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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A
B
Figure  2  scanning  electron  microscopy  microphotographs  of  chitosan  (cs) 
microparticles prepared by the spray-drying method: A) without tripolyphosphate 
pentasodium (TPP) and B) crosslinked with TPP (cs/TPP weight ratio of 6:1, w/w).
of modifying drug release rates as desired for masking the 
taste and proper absorption.
As part of the microencapsulation technique, the 
nanoparticle colloids mixed with CS and free drug were 
directly spray-dried together prior to spray-drying the final 
samples composed of centrifuged CS-NPs. During the aque-
ous ionotropic gelation process, water-soluble properties 
of SH might lead to low drug encapsulation efficiency. 
The   spray-drying was used to dramatically improve drug 
encapsulation   efficiency for the resulting microparticles. 
Drug content typically denotes the percentage of drug 
that is entrapped, while the encapsulation efficiency is 
calculated as the ratio of the drug content to the actual 
drug added. According to our previous studies, the drug 
LC improved as the drug/material ratios increased.16 Also, 
the drug content can be controlled using different weight 
ratios of SH to CS according to clinical needs. An adequate 
LC of 23.4% ± 2.6% was obtained for the selected SH:CS 
ratio of 1:4 (w/w). The production yield of spray-dried 
microparticles was about 65%, with satisfactory encapsula-
tion efficiencies of more than 90%.
Morphology of the cs microparticles 
produced by the spray-drying method
The shape and surface morphology of CS microparticles 
prepared by spray-drying were observed using SEM 
 ( Figure 2). As shown in Figure 2, the spray-dried micropar-
ticles were almost spherical, with a regular shape and a 
particle   diameter range of 1–5 µm. The observed small 
solid particles   (Figure 2) could have been formed from 
the spraying of a single minor droplet containing one or 
two CS nanoparticles. A few relatively rough-surfaced 
particles were found in the noncrosslinked CS micropar-
ticle sample (Figure 2A). Most of the TPP-crosslinked CS 
microparticles were found to be spherical with smooth 
surfaces (Figure 2B). These might have been some of the 
pre-existing nanoparticles that remained unreacted after 
ionotropic gelation with aqueous TPP.
Generally, the size of the noncrosslinked CS micropar-
ticles was smaller than that of the crosslinked microparticles 
(Figure 2). This effect is somewhat similar to that observed 
by Anal et al,18 who showed a slight influence of TPP on the 
particle diameter. In the presence of sufficient amounts of 
TPP, fusion of smaller nanoparticles occurs, giving rise to 
CS microparticles of considerably larger size. The multifunc-
tional TPP also might act here to facilitate intermicroparticle 
binding of the CS.
In vitro drug release behaviors  
of the spray-dried microparticles
The in vitro SH release profiles were obtained by relat-
ing the amount of SH released from microparticles to the 
amount of SH encapsulated. Figure 3 displays the drug 
release profiles of spray-dried CS microparticles and the 
effect of the crosslinker (TPP) on release rate. As shown in 
Figure 3, the release rate of noncrosslinked microparticles 
was significantly faster (P , 0.05) than that of crosslinked 
microparticles during the first 1.5 hours. The cumulative 
release percentage from the noncrosslinked micropar-
ticles exceeded 74% within 30 minutes. In contrast, only 
about 55% of the drug was released from microparticles 
crosslinked with TPP in 30 minutes (Figure 3). Statistical 
analysis of SH release values before 1.5 hours shows that 
there is a significant effect (P , 0.05) of the TPP. The 
addition of TPP is probably effective to occupy CS amino International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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groups. The crosslinking of CS microparticles with TPP 
could retard the release rate because of the decreased 
water solubility of CS in this formulation, which could be 
important for maintaining further sustained drug release. 
Therefore, the degradation and enzymatic digestion of 
CS-NPs would be required for accomplishing the release 
process.19 The delayed drug release from nanoparticle-
entrapped microparticles might be valuable in order to 
control the unpleasant taste and local stimulation of the 
formulated tablets in the mouth.
It was apparent that drug release showed a rapid initial 
burst effect in vitro. As shown in Figure 3, about 85% of 
drug was released from the spray-dried microparticles within 
1.5 hours. This initial burst release occurred because the drug 
was dispersed close to the surface of the particles. This portion 
of absorbed drug can be easily desorbed from the outer layer 
and will then diffuse out into solution. After 1.5 hours, similar 
drug release behavior for the two formulated microparticles 
(P . 0.05) could be found in Figure 3. Generally, noncross-
linked CS microparticles cannot be kept suspended in water 
because of their swellability and dissolvability. In order to 
prepare highly stabilized CS microparticles, other crosslink-
ing agents (glutaraldehyde or formaldehyde) are usually 
needed to solidify the microparticles.20
Disintegration time of ODTs
According to the description of Kuno et al,21 the preliminary 
test in volunteers was carried out previously. The oral disinte-
gration time of an ODMT put into the mouth of a healthy male 
adult volunteer without water was recorded as the time until the 
volunteer felt that the tablet had disappeared in his mouth. The 
recorded oral disintegration times were close to those resulting in 
the procedure used in the present study. The dynamic state of 30 
vibrations/minute was taken to mimic the condition in vivo.
Table 2 Disintegration times of orally disintegrating tablets with 
different drug dispersion states (n = 6)
Orally disintegrating tablets Disintegration time  
(mean ± standard  
deviation) (seconds)
conventional (free drug) 31 ± 2.6
With noncrosslinked microparticles 35 ± 2.0
With crosslinked microparticles 42 ± 1.7
The disintegration of a tablet was defined as the disap-
pearance of the bead-like structure as observed in the baskets 
of the disintegration time determinator. The time needed 
for complete disintegration of various ODTs with drugs in 
different states is shown in Table 2. All the prepared tablets 
disintegrated completely within 45 seconds. The developed 
formulations were therefore demonstrated to be “quickly 
dispersible” ODTs.
The disintegrating agent swells when it comes into 
contact with water in a very predictable manner. It absorbs 
water rapidly, resulting in swelling that leads to the rapid 
disintegration of the tablets and granules. The disintegrating 
agents employed in the formulations were composed of 35% 
weight percentage microcrystalline cellulose and 10% weight 
percentage carboxymethylstarch sodium (Table 1). These 
formulations appeared to be the main factor responsible for 
the variations in disintegrating times shown in Table 2.
Disintegration time, which might also be affected by 
the hardness of the tablets, is related to the nature of the 
disintegrating agent, which allows the tablet to break up 
into smaller fragments upon contact with physiologic fluids. 
According to the results of Kuno et al,21 tablets containing 
1% xylitol showed a suitable hardness and oral disintegra-
tion time. Therefore, 1% xylitol was also used in the ODMT 
formulation (Table 1) to ensure that the tablet hardness and 
disintegration properties were maintained.
Dissolution characteristics
ODTs disaggregate in the oral cavity, usually releasing the 
active agent and allowing it to dissolve remarkably quickly in 
the saliva. In this work, NiMS-based ODMTs were designed 
to overcome the local irritation to oral mucosa caused by the 
direct drug exposure from conventional ODTs.   Figure 4 shows 
the in vitro drug release profiles of conventional ODTs, 
NiMS-based ODMTs, and noncrosslinked ODMTs. For the 
conventional ODTs, 94.6% of the drug was released within 
only 3 minutes. In contrast, 70% or less of the SH was released 
from the two prepared ODMTs in 30 minutes, and the time 
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for 90% of drug release to occur was more than 90 minutes 
(Figure 4). The statistical analysis shows that the drug released 
very quickly from conventional ODTs (P , 0.01) compared 
with that from the two ODMT formulations. Formulation of 
a microencapsulated drug into ODTs, as in the present case, 
might result in this controlled, sustained release.
Figure 4 shows that the drug release rate of ODMTs 
formulated with crosslinked microparticles (NiMS-based 
ODMTs, 63% in 30 minutes and 85% in 90 minutes) was 
slower (P , 0.05) than that of ODMTs made with non-
crosslinked microparticles (noncrosslinked ODMTs, 70% 
in 30 minutes and 91% in 90 minutes). This behavior might 
be due to the retardant effect of TPP, in accordance with 
the behavior of the microparticles described previously 
 ( Figure 3). The controlled drug release could alleviate prob-
lems such as premature destruction of the tablet, unpleasant 
taste, or intense exposure to high concentrations of the active 
agent. Finally, it is important to note that the SH-NiMS, 
including novel ODMTs, could potentially improve com-
pliance with drug administration regimens and promote a 
remarkably steady rate of drug absorption.
Conclusion
The SH-entrapped NiMS was successfully prepared using 
an ionotropic gelation process combined with a spray-drying 
method. The developed ODMT formulation has advanta-
geous characteristics that distinguish it from commonly 
used ODTs. The presence of disaggregating agents makes it 
possible to produce a hard tablet that can still disaggregate 
within seconds and be considered “quickly dispersible”. The 
ODMTs can be formulated not only for oral dispersibility 
but also for delayed drug release that takes place far from 
the buccal region. Therefore, this novel ODMT prepared by 
means of a conventional tablet formation technique would be 
desirable to mask the drug taste in the oral cavity and lessen 
the common side effects related to the intrinsic characteristics 
of SH. Formulations containing NiMS represent an example 
of quickly dispersible/slowly releasing tablets that are an 
alternative to traditional ODTs.
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